Cite
HARVARD Citation
Alvarez, E. et al. (2022). Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Multiple sclerosis journal, experimental, translational and clinical. 8 (1), p. . [Online].